Literature DB >> 21276599

Identification and functional characterization of the Varicella zoster virus ORF11 gene product.

Xibing Che1, Stefan L Oliver, Marvin H Sommer, Jaya Rajamani, Mike Reichelt, Ann M Arvin.   

Abstract

The deletion of ORF11 severely impaired VZV infection of human skin xenografts. Here, we investigate the characteristics and functions of the ORF11 gene product. ORF11 is expressed as a 118kDa polypeptide in VZV-infected cells; the protein is present in the nucleus and cytoplasm and is incorporated into VZ virions. Although ORF11 had little effect in transactivating VZV gene promoters in transfection assays, deleting ORF11 from the virus was associated with reduced expression of immediate early proteins IE4, IE62 and IE63, and the major glycoprotein, gE. ORF11 was identified as an RNA binding protein and its RNA binding domain was defined. However, disrupting the ORF11 RNA binding domain did not affect skin infection, indicating that RNA binding capacity, conserved among the alphaherpesviruses homologues, is not essential while the contribution of ORF11 to the expression of the IE proteins and gE may be required for VZV pathogenesis in skin in vivo.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21276599      PMCID: PMC3068617          DOI: 10.1016/j.virol.2010.12.055

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  38 in total

Review 1.  RNA recognition by arginine-rich peptide motifs.

Authors:  M A Weiss; N Narayana
Journal:  Biopolymers       Date:  1998       Impact factor: 2.505

2.  Nucleocytoplasmic shuttling of bovine herpesvirus 1 UL47 protein in infected cells.

Authors:  Janneke Verhagen; Ian Hutchinson; Gillian Elliott
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  The ubiquitous cellular transcriptional factor USF targets the varicella-zoster virus open reading frame 10 promoter and determines virulence in human skin xenografts in SCIDhu mice in vivo.

Authors:  Xibing Che; Barbara Berarducci; Marvin Sommer; William T Ruyechan; Ann M Arvin
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

4.  Characterization of a novel transferable CRM-1-independent nuclear export signal in a herpesvirus tegument protein that shuttles between the nucleus and cytoplasm.

Authors:  Janneke Verhagen; Michelle Donnelly; Gillian Elliott
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  RNA binding by the herpes simplex virus type 1 nucleocytoplasmic shuttling protein UL47 is mediated by an N-terminal arginine-rich domain that also functions as its nuclear localization signal.

Authors:  Michelle Donnelly; Janneke Verhagen; Gillian Elliott
Journal:  J Virol       Date:  2006-12-13       Impact factor: 5.103

6.  Promoter activation by the varicella-zoster virus major transactivator IE62 and the cellular transcription factor USF.

Authors:  Min Yang; Hua Peng; John Hay; William T Ruyechan
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

7.  Varicella-zoster virus open reading frame 10 is a virulence determinant in skin cells but not in T cells in vivo.

Authors:  Xibing Che; Leigh Zerboni; Marvin H Sommer; Ann M Arvin
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

8.  Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis.

Authors:  Li Wang; Marvin Sommer; Jaya Rajamani; Ann M Arvin
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

9.  Functions of the ORF9-to-ORF12 gene cluster in varicella-zoster virus replication and in the pathogenesis of skin infection.

Authors:  Xibing Che; Mike Reichelt; Marvin H Sommer; Jaya Rajamani; Leigh Zerboni; Ann M Arvin
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

10.  Cellular and viral factors regulate the varicella-zoster virus gE promoter during viral replication.

Authors:  Barbara Berarducci; Marvin Sommer; Leigh Zerboni; Jaya Rajamani; Ann M Arvin
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

View more
  6 in total

1.  Varicella zoster virus infection of human fetal lung cells alters mitochondrial morphology.

Authors:  Amy C Keller; Hussain Badani; P Mason McClatchey; Nicholas L Baird; Jacqueline L Bowlin; Ron Bouchard; Guey-Chuen Perng; Jane E B Reusch; Benedikt B Kaufer; Don Gilden; Aamir Shahzad; Peter G E Kennedy; Randall J Cohrs
Journal:  J Neurovirol       Date:  2016-05-31       Impact factor: 2.643

2.  ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection.

Authors:  Xibing Che; Stefan L Oliver; Mike Reichelt; Marvin H Sommer; Jürgen Haas; Tihana L Roviš; Ann M Arvin
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

3.  Increase in the genetic polymorphism of varicella-zoster virus after passaging in in vitro cell culture.

Authors:  Hye Rim Hwang; Seok Cheon Kim; Se Hwan Kang; Chan Hee Lee
Journal:  J Microbiol       Date:  2019-10-28       Impact factor: 3.422

4.  The Tegument Protein pUL47 of Marek's Disease Virus Is Necessary for Horizontal Transmission and Is Important for Expression of Glycoprotein gC.

Authors:  Aurélien Chuard; Katia Courvoisier-Guyader; Sylvie Rémy; Stephen Spatz; Caroline Denesvre; David Pasdeloup
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

5.  Analysis of the reiteration regions (R1 to R5) of varicella-zoster virus.

Authors:  Nancy J Jensen; Daniel P Depledge; Terry Fei Fan Ng; Jessica Leung; Mark Quinlivan; Kay W Radford; Jennifer Folster; Hung-Fu Tseng; Philip LaRussa; Steven J Jacobsen; Judith Breuer; D Scott Schmid
Journal:  Virology       Date:  2020-04-04       Impact factor: 3.513

6.  Evolution of cocirculating varicella-zoster virus genotypes during a chickenpox outbreak in Guinea-Bissau.

Authors:  Daniel P Depledge; Eleanor R Gray; Samit Kundu; Samantha Cooray; Anja Poulsen; Peter Aaby; Judith Breuer
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.